(Sharecast News) - Avacta Therapeutics said on Thursday that it had made "important milestones" in the first quarter of 2026, as the clinical-stage oncology company advanced its preCISION platform and secured additional funding to support development through key data readouts later this year.
The AIM-traded group confirmed that its first Gen...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE